

# The potential of pirtobrutinib in multiple B-cell malignancies

Jeffrey L. Jensen, Anthony R. Mato , Camila Pena, Lindsey E. Roeker and Catherine C. Coombs

*Ther Adv Hematol*  
2022, Vol. 13: 1–10

DOI: 10.1177/  
20406207221101697

© The Author(s), 2022.  
Article reuse guidelines:  
[sagepub.com/journals-](https://sagepub.com/journals-permissions)  
[permissions](https://sagepub.com/journals-permissions)

**Abstract:** Bruton's tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell receptor (BCR) that has been effectively inhibited in B-cell cancers by irreversible, covalent inhibitors including ibrutinib and acalabrutinib. All FDA-approved covalent BTK inhibitors rely on binding to the cysteine 481 (C481) amino acid within the active site of BTK, thus rendering it inert. While covalent BTK inhibitors have been very successful in multiple B-cell malignancies, improving both overall survival and progression-free survival relative to chemoimmunotherapy in phase 3 trials, they can be limited by intolerance and disease progression. Pirtobrutinib is a novel, highly selective, and non-covalent BTK inhibitor that binds independently of C481, and in a recent, first-in-human phase 1/2 clinical trial was shown to be extremely well tolerated and lead to remissions in relapsed/refractory patients with multiple B-cell malignancies. Here, we review the pharmacologic rationale for pursuing non-covalent BTK inhibitors, the clinical need for such inhibitors, existing safety, and resistance mechanism data for pirtobrutinib, and the forthcoming clinical trials that seek to define the clinical utility of pirtobrutinib, which has the potential to fulfill multiple areas of unmet clinical need for patients with B-cell malignancies.

**Keywords:** acalabrutinib, BTK, CLL, ibrutinib, LOXO-305, non-covalent, pirtobrutinib

Received: 6 January 2022; revised manuscript accepted: 29 April 2022.

## Biology and pharmacology of BTK inhibition in B-cell cancers:

BTK is a non receptor, cytoplasmic tyrosine kinase in the Src subfamily encoded by the *BTK* gene on the X chromosome.<sup>1,2</sup> When mutated, the *BTK* gene confers B-cell development deficits with x-linked immunodeficiency in mice and agammaglobulinemia, the virtual absence of all B cells and immunoglobulins in humans. These deficits are thought to be mediated by disruption of downstream signaling from the BCR, which is known to transmit survival and proliferation signals in both healthy and malignant B cells.<sup>3</sup> Binding of the BCR in healthy B cells results in formation of a 'signalosome': A complex of kinases and scaffold proteins tethered to the plasma membrane that initiates a cascade of phosphorylation mediated by the tyrosine kinases LYN, SYK, and subsequently BTK. BTK signaling leads to activation of PLCG2 and production

of downstream second messengers inositol-1,4,5-triphosphate and diacylglycerol, activation of protein kinase C, and activation of transcription factors including NF- $\kappa$ B.<sup>2</sup>

BTK inhibition was first established as a valuable therapeutic target for B-cell cancers by ibrutinib: a potent small-molecule inhibitor of BTK that binds covalently to C481 in the active kinase domain of BTK.<sup>1</sup> In cell culture, it had a modest effect inducing apoptosis but with effective blockade of BCR signaling and the subsequent cytokine production (i.e., CCL3 and CCL4).<sup>4–7</sup> While ibrutinib binds readily to BTK, it also has off-target effects on at least 19 other kinases including BLK, BMX, ITK, TEC, EGFR, ERBB2, and JAK3. This non-specific activity is at least partially responsible for the side effects of ibrutinib.<sup>8,9</sup> For example, off-target TEC inhibition is attributed to some of the increased anti-platelet and

Correspondence to:  
**Catherine C. Coombs**  
Division of Hematology,  
Department of Medicine,  
The University of North  
Carolina at Chapel Hill,  
170 Manning Drive, Chapel  
Hill, NC 27599, USA.  
[calliecoombs@gmail.com](mailto:calliecoombs@gmail.com)

**Jeffrey L. Jensen**  
Department of Medicine,  
The University of North  
Carolina at Chapel Hill,  
Chapel Hill, NC, USA

**Anthony R. Mato**  
**Camila Pena**  
**Lindsey E. Roeker**  
Memorial Sloan Kettering  
Cancer Center, New York,  
NY, USA



bleeding activity of ibrutinib.<sup>10</sup> Acalabrutinib, a second-generation covalent BTK inhibitor that also binds C481, demonstrates much higher potency and selectivity for BTK over other kinases.<sup>8,9</sup> Similarly, zanubrutinib, another covalent BTK inhibitor, has potential selectivity benefits over ibrutinib. Due to covalent BTK inhibitor resistance mediated by C481 mutations, there was significant interest in the development of BTK inhibitors to target an alternate site as resistance mechanisms overlap for all currently available covalent BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib).<sup>11</sup> Further, covalent BTK inhibitors have short half-lives (e.g., 2–4 h for zanubrutinib) and the serum levels of covalent BTK inhibitors drop below their IC<sub>50</sub> levels using common dosing regimens possibly enabling tumor progression.<sup>12</sup> Theoretically, these irreversible inhibitors might be exhausted by BTK turnover, especially in aggressive tumors like Richter's transformation that are rapidly dividing and have low response rates to covalent BTK inhibitors.

To address mechanisms of resistance and tolerability issues, non-covalent BTK inhibitors have been developed and are at various stages of clinical testing: vecabrutinib, fenebrutinib, nemtabrutinib (MK-1026, formerly ARQ 531), and pirtobrutinib (formerly LOXO-305). Vecabrutinib was studied as monotherapy in a phase 1/2 dose escalation and expansion trial for CLL/SLL or non-Hodgkin's lymphoma, but this was terminated due to suboptimal activity (NCT03037645).<sup>13</sup> Fenebrutinib is being studied in autoimmune indications; there are no current clinical trials testing it in hematologic malignancies.<sup>14</sup> Preliminary results from the phase 2 dose-expansion study of nemtabrutinib in B-cell malignancies were recently presented, which included 51 CLL/SLL patients of whom 43 (84.3%) had prior BTK inhibitor therapy. Nemtabrutinib demonstrated an overall response rate (ORR) of 57.9% for 38 efficacy-evaluable CLL/SLL patients, with grade  $\geq$  3 treatment-emergent adverse effects in 68% of total participants (80 of 118).<sup>15</sup>

Pirtobrutinib is a novel third generation, non-covalent BTK inhibitor that inhibits BTK independently of C481 mutations in Waldenstrom's macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCL), and CLL cells.<sup>16–18</sup> It has marked selectivity with more than 300-fold selectivity for BTK over 98% of other kinases with

nanomolar potency against both wild-type and C481-mutant BTK in cell and enzyme assays.<sup>16,19,20</sup> In murine xenograft models with the DLBCL line TDM8, pirtobrutinib exhibited efficacy nearly identical to ibrutinib with BTK wild-type tumor cells but conferred significant improvements in efficacy with BTK-C481S mutants, with nearly half the mass dosing of pirtobrutinib (pirtobrutinib 30 mg/kg BID *versus* ibrutinib 50 mg/kg BID).<sup>21</sup> In contrast to covalent BTK inhibitors, pirtobrutinib is also able to maintain plasma levels above the BTK IC<sub>90</sub> with well-tolerated daily dosing.<sup>12,17</sup>

### Clinical successes and limitations of covalent BTK inhibitors

Since the clinical introduction of ibrutinib in 2011, covalent BTK inhibitors have been established as standard of care for a number of B-cell malignancies though an unmet clinical need persists for many patients. Here, we will focus on the role of existing BTK inhibitors for four malignancies: CLL/SLL, mantle cell lymphoma (MCL), WM, and Richter's transformation (RT) to set the stage for the current areas of unmet need that availability of pirtobrutinib might fill.

#### CLL/SLL

After ibrutinib was granted accelerated FDA approval based on phase 2 studies, ibrutinib was tested in randomized phase 3 trials for both relapsed/refractory and untreated CLL and performed admirably with improvements in progression-free survival (PFS) and overall survival (OS). Ibrutinib was superior to ofatumumab in the relapsed/refractory setting,<sup>22</sup> superior to chlorambucil as frontline treatment,<sup>23</sup> superior to bendamustine and rituximab as frontline treatment,<sup>24</sup> and superior to FCR chemotherapy as frontline therapy.<sup>25</sup> Taken together, these results demonstrated that ibrutinib with or without rituximab was an efficacious therapy and generally superior in both upfront and relapsed/refractory settings to chemoimmunotherapy or anti-CD20 monoclonal antibodies alone.

Next-generation covalent BTK inhibitors have had similar successes in randomized phase 3 CLL trials, both compared with standard-of-care agents and against ibrutinib. Acalabrutinib has shown improved PFS compared with idelalisib and compared with chemoimmunotherapy.<sup>25,26</sup> Acalabrutinib was also non-inferior to ibrutinib in

PFS but with lower rates of atrial fibrillation/flutter and hypertension.<sup>27</sup> Finally, in the first interim analysis of the ALPINE trial that compared zanubrutinib to ibrutinib, zanubrutinib led to a higher ORR, longer PFS, and a lower rate of atrial fibrillation/flutter.<sup>28</sup>

Covalent BTK inhibitors are commonly discontinued in real-world practice because of toxicities and disease progression. In a series of 616 CLL patients treated with ibrutinib, 41% of patients had discontinued ibrutinib within a median follow-up time of 17 months.<sup>29</sup> Among those discontinuations, nearly half were secondary to adverse events including atrial fibrillation, infectious complications, and cytopenias. Disease progression accounted for approximately 20% of discontinuations and RT accounted for approximately 5% of discontinuations. The first real-world studies with acalabrutinib (mostly in ibrutinib intolerant patients) show lower discontinuation rates (19%), albeit with shorter follow-up, with a similar proportion discontinuing for toxicity (8 of 13 patients).<sup>30</sup>

Disease progression in CLL through covalent BTK inhibitors is clearly associated with the previously mentioned *BTK-C481* mutations, but also with *PLCG2* mutations, which can occur in isolation or in conjunction with a BTK mutation.<sup>11,31</sup> Inhibition of *BTK-C481* mutated cell growth by BTK inhibitors that do not rely on C481 binding gives strong evidence that *BTK* mutations are causative for the development of resistance.<sup>32</sup> As *PLCG2* is activated by upstream signaling from BTK, *PLCG2* mutations are thought to be activating mutations and have been found more broadly throughout multiple domains of the *PLCG2* protein.<sup>33</sup> Interestingly, certain *PLCG2* mutations are more or less common depending on the co-occurrence of *BTK* mutations, implying cooperation between *BTK* and *PLCG2* in overcoming ibrutinib therapy.<sup>33</sup>

Among patients progressing on BTK inhibitors, options are limited though venetoclax has shown success in both clinical trials and using real-world evidence.<sup>34–36</sup> PI3 K inhibitors including idelalisib and duvelisib were studied prospectively in BTK inhibitor naïve patients<sup>37,38</sup> and have limited success (median PFS 7 months) in patients who have previously progressed on a covalent BTK inhibitor in real-world studies.<sup>39</sup> Rates of allogeneic stem cell transplants for CLL have been decreasing in

the United States and in Europe since the introduction of BTK inhibitors, but high-risk CLL patients that are suitable transplant candidates and are failed by covalent BTK inhibitors and venetoclax have limited treatment options and still undergo transplant in modern practice.<sup>40–42</sup> However, most refractory CLL patients are elderly and not considered transplant candidates. Patients who have previously been exposed to both BTK inhibitors and venetoclax represent a major area of unmet need. In the largest real-world study to date of ‘double-exposed’ CLL patients (prior treatment with venetoclax and covalent BTK inhibitors), PFS depended on the next line of therapy. Median PFS was 5 months for PI3 K inhibitors, 11 months for allogeneic stem cell transplant, 4 months for CAR T-cell therapy, and only 3 months for chemoimmunotherapy but among 40 patients that received a non-covalent BTK inhibitor the median PFS was not reached (median follow-up of 9 months).<sup>43</sup> In another study that did not include non-covalent BTK inhibitors, patients that progressed through a covalent BTK inhibitor and through venetoclax had a dismal OS of 3.6 months.<sup>44</sup> In summary, while covalent BTK inhibitors are mainstay therapy for both upfront and relapsed/refractory CLL, there are limited therapeutic options for patients failed by a covalent BTK and venetoclax due to either CLL progression, drug toxicities, or RT.

#### *Mantle cell lymphoma*

MCL is an incurable B-cell lymphoma with poor long-term outcomes. Generally treated with chemoimmunotherapy with or without autologous stem cell transplant upfront in fit patients, covalent BTK inhibitors are reserved for frontline treatment in frail patients or in the relapsed/refractory MCL setting.<sup>45</sup> BTK inhibitors were introduced in the relapsed/refractory setting after a phase 2 trial showed ibrutinib to have durable single-agent efficacy.<sup>46</sup> A phase 3 trial comparing ibrutinib to temsirolimus demonstrated an improved ORR, PFS, tolerability, and a trend toward an OS benefit for ibrutinib.<sup>47,48</sup> Ibrutinib has also been used in combination with venetoclax and in combination with lenalidomide and rituximab in phase 2 trials.<sup>49,50</sup> Both acalabrutinib and zanubrutinib received FDA approval for relapsed MCL based on phase 2 monotherapy trials with median PFS of 19.5 months and 21.1 months, respectively.<sup>51–53</sup> Recent real-world studies have confirmed similar lengths of PFS for

patients with relapsed MCL treated with BTK inhibitors.<sup>54</sup> *BTK*-C481 mutations are less commonly observed among MCL patients progressing on covalent BTK inhibitors, where *TP53* alterations occur in 75% of cases.<sup>55</sup>

Patients have few therapeutic options following progression on a covalent BTK inhibitor; chimeric antigen receptor (CAR)-T cells are one approach but these are limited to patients with access to tertiary referral centers.<sup>56</sup> Retrospective studies demonstrate short OS following progression on ibrutinib, ranging from 2.9 to 5.5 months.<sup>57,58</sup> Patients with MCL are also similarly susceptible to the toxicities of non-covalent BTK inhibitors including cytopenias, infections, atrial fibrillation, and bleeding.<sup>59</sup>

#### *Waldenstrom's macroglobulinemia*

WM is a rare B-cell lymphoma characterized by elevated serum levels of IgM and proliferation of IgM-producing lymphoplasmacytic cells. Owing to the rarity of WM, there have been few phase 3 randomized studies conducted. iNNOVATE was a randomized, double-blind, placebo-controlled phase 3 study of ibrutinib or placebo in combination with rituximab in patients with either treatment-naïve or relapsed WM.<sup>60</sup> PFS at 30 months was 82% among the ibrutinib-rituximab treatment arm and 28% in the placebo-rituximab arm ( $p < 0.001$ ). This effect was independent of *MYD88* and *CXCR4* mutational status and persisted in subgroup analyses of treatment-naïve or relapsed WM patients. These compelling results led ibrutinib to become the first FDA-approved therapy for WM. More recently, the ASPEN trial, a head-to-head, phase 3 trial comparing ibrutinib and zanubrutinib showed a similar complete response (CR) and very good partial response (VGPR) rates (28% versus 19% for zanubrutinib and ibrutinib, respectively with  $p = 0.09$ ), but zanubrutinib was better tolerated with lower rates of atrial fibrillation and other toxicities.<sup>61</sup> The ORR for zanubrutinib-treated patients improved with 3 years of follow-up of the original phase 1/2 trial (ORR 95.9%, VGPR/CR 45.2%).<sup>62</sup> Ibrutinib and chemoimmunotherapy are mainstays of therapy in both the treatment naïve and relapsed/refractory setting with venetoclax and proteasome inhibitor regimens reserved for BTK inhibitor relapse.<sup>63</sup> Mechanisms of relapse in the setting of WM include C481 and PLCG2 mutations.<sup>64</sup>

#### *Richter's transformation*

RT, especially when clonally related to the underlying CLL, carries extremely poor outcomes and inadequate treatment strategies. A variety of chemoimmunotherapy regimens have been utilized such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), and OFAR (oxaliplatin, fludarabine, ara-C, and rituximab) though with low CR rates and short PFS.<sup>65–67</sup> Responses to ibrutinib and acalabrutinib for relapsed/refractory RT have been demonstrated in small series, though the duration of response is typically short lived (3–6 months median duration response).<sup>68,69</sup> Moreover, as BTK inhibitors have become frontline therapy for CLL in both previously untreated and relapsed/refractory CLL patients, the proportion of covalent BTK inhibitor naïve patients have decreased which may further decrease the response rate upon transformation.<sup>70</sup>

#### **Clinical evaluation of pirtobrutinib to date**

The first-in-human clinical trial of pirtobrutinib was a multicenter phase 1/2 study (BRUIN) in patients with CLL, MCL, WM, and other B-cell lymphomas. Eligible patients were exposed to either one to two prior lines of therapy (CLL/SLL eligible after frontline covalent BTK inhibitor after fifth study amendment) with endpoints of maximum tolerated dose (MTD) (phase 1) and ORR (phase 2).<sup>17,21</sup> Pirtobrutinib was well tolerated at all dose levels, with no dose-limiting toxicities. Subsequently, an MTD was not reached, and 200 mg daily was selected as the recommended phase 2 dose. Atrial fibrillation occurred in less than 1% of patients, which was considered unrelated to pirtobrutinib due to a history of previous atrial fibrillation in affected patients. Hemorrhage, another common covalent BTK inhibitor toxicity, was seen in less than 5% of patients, with only one grade 3 event due to a subarachnoid hemorrhage sustained in a bicycle accident. The most common adverse events were fatigue (20%), diarrhea (17%), contusions (13%), and neutropenia (13%). 87% of adverse events were grade 1 or 2, and the most common grade  $\geq 3$  adverse event was neutropenia, with neutropenia reflecting the only grade 4 adverse event. Upper respiratory infections were the most common infection, seen in 7% of patients.<sup>17</sup>



**Table 1.** Ongoing phase 3 clinical trials with pirtobrutinib.

Trial	Population	Experimental Arm	Control Arm
NCT05023980, phase 3	Untreated CLL/SLL	Pirtobrutinib	Bendamustine + Rituximab
NCT04965493, phase 3	Previously treated CLL/SLL	Pirtobrutinib + Venetoclax + Rituximab	Venetoclax + Rituximab
NCT04666038, phase 3	BTK inhibitor pre-treated CLL/SLL	Pirtobrutinib	Investigator's choice of Idelalisib + Rituximab or Bendamustine + Rituximab
NCT04662255, phase 3	Previously treated, BTK inhibitor naïve MCL	Pirtobrutinib	Investigator choice of covalent BTK Inhibitor

BTK, Bruton's tyrosine kinase; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma.

At time of initial publication, 323 patients with a variety of B-cell malignancies have been treated. Efficacy varied among tumor type. ORR was 63%, 52%, and 68% among CLL/SLL, MCL, and WM, respectively. Similar response rates were seen in limited cohorts for follicular lymphoma ( $N=8$ , ORR 50%) and in RT ( $N=8$ , ORR = 75%). Within CLL/SLL, the ORR and the quality of responses were found to increase with time even in a heavily pre-treated cohort of patients, and a remarkably high proportion of patients (88%) remained on pirtobrutinib with a median follow-up period of ~6 months. Response rates were similar between all patients and those previously treated with BTK inhibitors in CLL/SLL (63% and 62%, respectively), MCL (52% for both), and WM (68% and 69%, respectively). In both CLL and MCL, highly refractory patients who had previously received cellular therapies including CAR-T cells and stem cell transplants (autologous and allogeneic) were among the responders. As expected, patients harboring *BTK* C481 mutations were also among the responders. In fact, CLL/SLL patients previously treated with a covalent BTK inhibitor with a *BTK* C481 mutation had similar response rates to those who had wild-type *BTK*. Response rates also seemed unaffected by *TP53* mutation status, 17p deletion, or both.<sup>17</sup>

An expanded dataset for patients with RT was subsequently presented, demonstrating the efficacy of this drug in this otherwise difficult to treat disease.<sup>71</sup> The drug was tolerated in the RT population with similar rates of adverse reactions as to those in the study at large. ORR among

DLBCL patients were lower than for other B-cell lymphomas, with only six of 25 (24%) patients with DLBCL having a response. Of those six who did respond, three only stayed on pirtobrutinib for 3 months and then discontinued. The other three remained on treatment at the time of publication with treatment times of 2.4, 7.1, and 9.6 months. This was in a heavily pre-treated cohort, with the 25 patients having 3–5 prior lines of therapy (median = 4).<sup>17</sup>

### The future of pirtobrutinib

Several clinical trials, summarized in Table 1, are ongoing to establish the role for pirtobrutinib in the treatment of B-cell malignancies. NCT04666038 (BRUIN CLL-321) randomizes patients to pirtobrutinib or investigator's choice of either idelalisib plus rituximab or bendamustine plus rituximab and requires previous treatment with a covalent BTK inhibitor. Notably, prior venetoclax therapy is not required for enrollment on this trial. If positive, this trial could lead to approval of pirtobrutinib in the post-covalent BTKi setting, which would allow for an additional therapeutic option for patients who have either contraindications to venetoclax therapy such as significant renal disease or inability to complete the required dose ramp necessary for tumor lysis syndrome monitoring. In addition, availability of pirtobrutinib could also help fill an existing major area of unmet need in CLL—an effective therapy for post-covalent BTKi and post-venetoclax treated patients.<sup>44</sup> Real-world data cited previously already suggests that in 'double-exposed' patients, treatment with a non-covalent BTK

inhibitor leads to longer PFS than PI3 K inhibitors or chemoimmunotherapy.<sup>43</sup>

NCT04965493 (BRUIN CLL-322) investigates the addition of fixed-duration pirtobrutinib to venetoclax and rituximab compared with venetoclax and rituximab alone in patients with at least 1 prior line of therapy (not required to be a covalent BTK inhibitor). This study seeks to improve on the existing efficacy of the MURANO regimen of venetoclax and rituximab, which leads to a median PFS of 53.6 months.<sup>72,73</sup> Few patients in the original MURANO trial had prior BTK inhibitors, though by design one would expect ~80% patients in this trial to have had prior covalent BTK inhibition, so the median PFS may differ even in the control arm. Should pirtobrutinib improve the efficacy of venetoclax and rituximab alone, this may become an attractive therapeutic option especially for younger, fitter patients seeking a time-limited therapy option.

NCT05023980 (BRUIN CLL-313) investigates pirtobrutinib as frontline therapy for CLL/SLL compared with bendamustine and rituximab. Similar to other trials comparing continuous BTK inhibition in the frontline setting to the bendamustine and rituximab regimen,<sup>24,74</sup> it is plausible that this will be a positive trial and may then allow for the approval of pirtobrutinib in the frontline setting. If the tolerability profile remains similar, then pirtobrutinib could lead to significant improvements in patient outcomes given the known high rate of discontinuation of other covalent inhibitors.<sup>29</sup>

In MCL, NCT04662255 is currently recruiting patients and investigates previously treated MCL patients that are BTK inhibitor-naïve. Patients will be randomized to receive either pirtobrutinib or the investigator's choice of the three FDA-approved covalent BTK inhibitors, with a primary endpoint of PFS. Should pirtobrutinib lead to superior PFS, this may lead to improved outcomes among MCL patients needing BTK inhibitor therapy. This study will also provide valuable information regarding the head-to-head toxicity profiles of pirtobrutinib with covalent BTK inhibitors.

Multiple lines of evidence in cell culture, xenografts, and clinical trials suggest that pirtobrutinib can effectively treat C481-mutated tumor clones.<sup>21</sup> Recently published data based on the

sequencing of heavily pre-treated CLL patients before and after developing pirtobrutinib resistance have implicated non-C481, *BTK* kinase domain mutations (V416 L, A428D, M437R, T474I, and L528 W) and *PLCG2* mutations as resistance mechanisms for pirtobrutinib.<sup>75</sup> The numbers in this initial study are small, only evaluating nine patients with pirtobrutinib resistance, but all nine pirtobrutinib-resistant patients had *BTK* kinase domain mutations or *PLCG2* mutations. Cell line studies were also consistent with these kinase domain mutations conferring both non-covalent and covalent BTK inhibitor resistance, raising the concern that pirtobrutinib-refractory patients might largely be refractory to covalent BTK inhibitors in the covalent BTK inhibitor-naïve setting, but it is unknown if patients treated with pirtobrutinib earlier in their disease course will develop these same mechanisms of genetic escape. It will also need to be determined if patients with WM, MCL, or RT develop these same mutations.

## Conclusion

Inhibiting BTK has yielded remarkable gains for patients with B-cell malignancies, and the development of pirtobrutinib furthers these gains by introducing a new treatment option for patients with CLL/SLL, MCL, and other lymphomas. Pirtobrutinib circumvents C481 mutations as a genetic mechanism of resistance for covalent BTK inhibitors, extending the utility of BTK inhibition in the management of these diseases by creating an additional line of therapy for patients with covalent BTK-inhibitor-refractory disease. Pirtobrutinib is also highly selective for BTK, with resultant tolerability leading to few discontinuations for adverse events,<sup>17</sup> and thus far has favorably low rates of atrial fibrillation when compared with rates seen with covalent BTK inhibitors.<sup>27</sup> While the majority of ongoing trials are focusing on CLL/SLL, forthcoming data in MCL may also establish a role for pirtobrutinib in the relapsed/refractory disease setting where progress is greatly needed. In addition, there may be a role for pirtobrutinib in other aggressive B-cell cancers including RT, diseases for which advances are needed given such poor outcomes observed with existing therapies. Pirtobrutinib further builds on the success of covalent BTK inhibitors, demonstrating activity in patients with BTK-inhibitor-refractory disease and safety with an excellent adverse event profile. Multiple trials are

ongoing, which will further inform the optimal use of pirtobrutinib, and FDA approval of pirtobrutinib is anticipated

### Author contribution(s)

**Jeffrey L. Jensen:** Conceptualization; Writing – original draft.

**Anthony R. Mato:** Conceptualization; Writing – review & editing.

**Camila Pena:** Writing – review & editing.

**Lindsey E. Roeker:** Conceptualization; Writing – review & editing.

**Catherine C. Coombs:** Conceptualization; Writing – review & editing.

### ORCID iD

Anthony R. Mato  <https://orcid.org/0000-0001-5615-2247>

### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

### Conflict of interest statement

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.L.J. is an AbbVie shareholder. A.R.M. receives research support from TG Therapeutics, Pharmacyclics, Abbvie, Adaptive Biotechnologies, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, BeiGene, Genentech, Genmab, Janssen, Loxo Oncology, Nurix, and does advisory/consultancy/DSMB work with TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, Abbvie, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, AstraZeneca, BeiGene, Genentech, Janssen, Loxo Oncology. L.E.R. has served as a consultant for AbbVie, AstraZeneca, Beigene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, TG Therapeutics, and Vaniam group, holds minority ownership interest in Abbott Laboratories, and has received research funding (paid to the institution) from Pfizer, Loxo Oncology, and Aptose Biosciences. C.C.C. has served as a consultant for AbbVie, has served on steering committees for AbbVie and Loxo Oncology, has served on independent review committees for AbbVie and Octapharma, has received honoraria from AbbVie, AstraZeneca,

Beigene, Genentech, LOXO Oncology, MEI Pharma, Novartis, TG Therapeutics, and has received research funding (paid to the institution) from H3 Biomedicine, Incyte, Loxo Oncology.

### References

1. Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. *Curr Hematol Malig Rep* 2013; 8: 1–6.
2. Qiu Y and Kung H-J. Signaling network of the Btk family kinases. *Oncogene* 2000; 19: 5651–5661.
3. Stevenson FK, Krysov S, Davies AJ, *et al.* B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2011; 118: 4313–4320.
4. Zheng X, Ding N, Song Y, *et al.* Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. *Cancer Cell International* 2014; 14: 32.
5. de Rooij MF, Kuil A, Geest CR, *et al.* The clinically active BTK inhibitor PCI-32765 targets B-cell receptor–and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. *Blood J Am Soc Hematol* 2012; 119: 2590–2594.
6. Herman SE, Gordon AL, Hertlein E, *et al.* Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood J Am Soc Hematol* 2011; 117: 6287–6296.
7. Ponader S, Chen S-S, Buggy JJ, *et al.* The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. *Blood* 2012; 119: 1182–1189.
8. Lipsky A and Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. *Hematology* 2020; 2020: 336–345.
9. Patel V, Balakrishnan K, Bibikova E, *et al.* Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. *Clin Cancer Res* 2017; 23: 3734–3743.
10. Shatzel JJ, Olson SR, Tao DL, *et al.* Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. *J Thromb Haemost* 2017; 15: 835–847.
11. Woyach JA, Ruppert AS, Guinn D, *et al.* BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. *J Clin Oncol* 2017; 35: 1437–1443.

12. Tam CS, Ou YC, Trotman J, *et al.* Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. *Expert Rev Clin Pharmacol* 2021; 14: 1329–1344.
13. Aslan B, Hubner SE, Fox JA, *et al.* Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase. *Haematologica* 2022; 107: 292–297.
14. Isenberg D, Furie R, Jones NS, *et al.* Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. *Arth Rheumatol* 2021; 73: 1835–1846.
15. Woyach J, Flinn IW, Awan FT, *et al.* Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study. *American Society of Hematology Annual Meeting* 2021; 138: 392.
16. Munshi M, Liu X, Kofides A, *et al.* Pirtobrutinib (LOXO-305) is active and overcomes ERK related pro-survival signaling in ibrutinib resistant, BTK Cys481 mutant expressing WM and ABC DLBCL lymphoma cells driven by activating MYD88 mutations. *Blood* 2021; 138: 2261.
17. Mato AR, Shah NN, Jurczak W, *et al.* Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet* 2021; 397: 892–901.
18. Catherine C, Coombs JMP, Shah NN, *et al.* Mato Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: results from the phase 1/2 BRUIN study. *Clin Lymph Myel Leuk* 2021; 21: S315–S316.
19. Lewis KL and Cheah CY. Non-covalent BTK inhibitors – the new BTKids on the block for B-Cell malignancies. *J Pers Med* 2021; 11: 764.
20. Brandhuber B, Gomez E, Smith S, *et al.* LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. *Clin Lymph Myel Leuk* 2018; 18: S216.
21. Coombs C, Pagel J, Shah N, *et al.* Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: results from the phase 1/2 BRUIN study. In: *Society of hematologic oncology annual meeting*, Houston, TX (virtual meeting), 2021.
22. Byrd JC, Brown JR, O'Brien S, *et al.* Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *New Engl J Med* 2014; 371: 213–223.
23. Burger JA, Tedeschi A, Barr PM, *et al.* Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *New Engl J Med* 2015; 373: 2425–2437.
24. Woyach JA, Ruppert AS, Heerema NA, *et al.* Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med* 2018; 379: 2517–2528.
25. Ghia P, Pluta A, Wach M, *et al.* ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. *J Clin Oncol* 2020; 38: 2849–2861.
26. Sharman JP, Banerji V, Fogliatto LM, *et al.* ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (o) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naïve chronic lymphocytic leukemia (CLL). *Blood* 2019; 134(Suppl. 1): 31.
27. Byrd JC, Hillmen P, Ghia P, *et al.* Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. *J Clin Oncol* 2021; Jco2101210.
28. Hillmen P, Eichhorst B, Brown J, *et al.* First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. *European Hematology Association* 2021; 2021: LB1900.
29. Mato AR, Nabhan C, Thompson MC, *et al.* Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. *Haematologica* 2018; 103: 874–879.
30. Yazdy MS, Mato AR, Roeker LE, *et al.* Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients. *Blood* 2019(Suppl. 1): 4311–4311.
31. Liu TM, Woyach JA, Zhong Y, *et al.* Hypermorphic mutation of phospholipase C,  $\gamma^2$  acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. *Blood* 2015; 126: 61–68.
32. Johnson AR, Kohli PB, Katewa A, *et al.* Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. *ACS Chem Biol* 2016; 11: 2897–2907.



33. Jones D, Woyach JA, Zhao W, *et al.* PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. *Leukemia*; 31: 1645–1647.
34. Jones JA, Mato AR, Wierda WG, *et al.* Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncol* 2018; 19: 65–75.
35. Eyre TA, Kirkwood AA, Gohill S, *et al.* Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. *Br J Haematol* 2019; 185: 656–669.
36. Mato AR, Thompson M, Allan JN, *et al.* Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. *Haematologica* 2018; 103: 1511–1517.
37. Flinn IW, Hillmen P, Montillo M, *et al.* The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. *Blood* 2018; 132: 2446–2455.
38. Sharman JP, Coutre SE, Furman RR, *et al.* Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. *J Clin Oncol* 2019; 37: 1391–1402.
39. Mato AR, Nabhan C, Barr PM, *et al.* Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. *Blood* 2016; 128: 2199–2205.
40. Gribben JG. How and when I do allogeneic transplant in CLL. *Blood* 2018; 132: 31–39.
41. Lahoud OB, Devlin SM, Maloy MA, *et al.* Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. *Blood Adv* 2021; 5: 2879–2889.
42. Roeker LE, Dreger P, Brown JR, *et al.* Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. *Blood Adv* 2020; 4: 3977–3989.
43. Thompson M, Roeker L, Coombs C, *et al.* Addressing a new challenge in chronic lymphocytic leukemia: outcomes of therapies after exposure to both a covalent Bruton's tyrosine kinase inhibitor and venetoclax. *American Society of Hematology Annual Meeting* 2021; 138: 2628.
44. Lew TE, Lin VS, Cliff ER, *et al.* Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. *Blood Adv* 2021; 5: 4054–4058.
45. Maddocks K. Update on mantle cell lymphoma. *Blood* 2018; 132: 1647–1656.
46. Wang ML, Rule S, Martin P, *et al.* Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. *New Engl J Med* 2013; 369: 507–516.
47. Dreyling M, Jurczak W, Jerkeman M, *et al.* Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. *Lancet* 2016; 387: 770–778.
48. Rule S, Jurczak W, Jerkeman M, *et al.* Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. *Leukemia* 2018; 32: 1799–1803.
49. Tam CS, Anderson MA, Pott C, *et al.* Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. *New Engl J Med* 2018; 378: 1211–1223.
50. Jerkeman M, Eskelund CW, Hutchings M, *et al.* Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Haematol* 2018; 5: e109–e116.
51. Wang M, Rule S, Zinzani PL, *et al.* Acabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. *Lancet* 2018; 391: 659–667.
52. Wang M, Rule S, Zinzani PL, *et al.* Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. *Blood* 2018; 132: 2876.
53. Tam CS, Opat S, Simpson D, *et al.* Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. *Blood Adv* 2021; 5: 2577–2585.
54. McCulloch R, Lewis D, Crosbie N, *et al.* Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. *Br J Haematol* 2021; 193: 290–298.
55. Jain P, Kanagal-Shamanna R, Zhang S, *et al.* Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. *Br J Haematol* 2018; 183: 578–587.
56. Wang M, Munoz J, Goy A, *et al.* KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *New Engl J Med* 2020; 382: 1331–1342.

57. Rai S, Tanizawa Y, Cai Z, *et al.* MCL-041: outcomes for recurrent mantle cell lymphoma post-BTK inhibitor therapy in Japan: an administrative database study. *Clin Lymph Myel Leuk* 2021; 21: S407–S408.
58. Martin P, Maddocks K, Leonard JP, *et al.* Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood* 2016; 127: 1559–1563.
59. Jain P, Romaguera J, Srouf SA, *et al.* Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). *Br J Haematol* 2018; 182: 404–411.
60. Dimopoulos MA, Tedeschi A, Trotman J, *et al.* Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. *New Engl J Med* 2018; 378: 2399–2410.
61. Tam CS, Opat S, D’Sa S, *et al.* A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. *Blood* 2020; 136: 2038–2050.
62. Trotman J, Opat S, Gottlieb D, *et al.* Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. *Blood* 2020; 136: 2027–2037.
63. Dimopoulos MA and Kastritis E. How I treat Waldenström macroglobulinemia. *Blood* 2019; 134: 2022–2035.
64. Jiménez C, Chan GG, Xu L, *et al.* Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. *Br J Haematol* 2020; 189: 1165–1170.
65. Langerbeins P, Busch R, Anheier N, *et al.* Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. *Am J Hematol* 2014; 89: E239–E243.
66. Tsimberidou AM, Wierda WG, Plunkett W, *et al.* Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 2008; 26: 196–203.
67. Rogers KA, Huang Y, Ruppert AS, *et al.* A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. *Br J Haematol* 2018; 180: 259–266.
68. Hillmen P, Schuh A, Eyre TA, *et al.* Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE-CL-001 clinical study. *Blood* 2016; 128: 60.
69. Tsang M, Shanafelt TD, Call TG, *et al.* The efficacy of ibrutinib in the treatment of Richter syndrome. *Blood* 2015; 125: 1676–1678.
70. Rossi D, Spina V and Gaidano G. Biology and treatment of Richter syndrome. *Blood* 2018; 131: 2761–2772.
71. Mato A, Shah N, Lamanna N, *et al.* Pirtobrutinib (LOXO-305), a next generation, highly selective, non-covalent BTK inhibitor in previously treated Richter transformation: results from the phase 1/2 Bruin study. European Hematology Association, 2021, p. EP524, [https://www.loxoncology.com/docs/presentations/Mato\\_EP524\\_EHA\\_BRUIN\\_RT\\_FINAL.pdf](https://www.loxoncology.com/docs/presentations/Mato_EP524_EHA_BRUIN_RT_FINAL.pdf)
72. Seymour JF, Kipps TJ, Eichhorst B, *et al.* Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *New Engl J Med* 2018; 378: 1107–1120.
73. Kater A, Kipps T, Eichhorst B, *et al.* Five-year analysis of murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx). *Blood* 2020; 136: 19–21.
74. Tam C, Giannopoulos K, Jurczak W, *et al.* SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). *Blood* 2021; 138: 396.
75. Wang E, Mi X, Thompson MC, *et al.* Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. *New Engl J Med* 2022; 386: 735–743.